Investigating personalized treatment options for Idiopathic Pulmonary Fibrosis using genetic information
Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) trial and Molecular Endophenotyping in Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases study
This study is looking to make treatments for Idiopathic Pulmonary Fibrosis (IPF) better by using genetic information to find out how different people respond to medications like N-Acetylcysteine, so that doctors can provide more personalized care for patients with lung diseases.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-11071971 on NIH RePORTER |
What this research studies
This research focuses on improving the diagnosis and treatment of Idiopathic Pulmonary Fibrosis (IPF) by utilizing genetic information to tailor antifibrotic therapies. It aims to identify specific genetic variants that may influence how patients respond to treatments like N-Acetylcysteine (NAC). By collaborating with the Pulmonary Fibrosis Foundation, the study will analyze data from patients with interstitial lung diseases to better understand their conditions and optimize treatment strategies. The research employs advanced statistical methods to ensure robust analysis and interpretation of the data collected.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Idiopathic Pulmonary Fibrosis or other interstitial lung diseases who are willing to provide genetic samples and participate in follow-up studies.
Not a fit: Patients with interstitial lung diseases who do not have a genetic predisposition relevant to the study or those who are not willing to participate in genetic testing may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective, personalized treatment options for patients with IPF, improving their health outcomes.
How similar studies have performed: Previous research has shown promise in using genetic information to tailor treatments for other conditions, suggesting that this approach could be beneficial for IPF as well.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Spino, Catherine a — University of Michigan at Ann Arbor
- Study coordinator: Spino, Catherine a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.